Analysis of gout recurrences in first year of follow-up in patients with an incident diagnosis of gout
| Cases (n) | Person years | Incidence rate per 100 (95% CI) | |
|---|---|---|---|
| Total | 576 | 3011.6 | 19.1 (17.6 to 20.8) |
| Sex | |||
| Men | 455 | 2230.6 | 20.4 (18.6 to 22.4) |
| Women | 121 | 781.0 | 15.5 (12.9 to 18.5) |
| Age groups (years) | |||
| <45 | 32 | 219.2 | 14.6 (10.0 to 20.6) |
| 45–64 | 192 | 955.2 | 20.1 (17.4 to 23.2) |
| >65 | 352 | 1837.1 | 19.2 (17.2 to 21.3) |
| Geographical area | |||
| Northern Italy | 253 | 1393.1 | 18.2 (16.0 to 20.5) |
| Central Italy | 72 | 470.0 | 15.3 (12.0 to 19.3) |
| Southern Italy | 251 | 1148.6 | 21.9 (19.2 to 24.7) |
| Comorbidity | |||
| Hypertension | 376 | 1931.7 | 19.5 (17.5 to 21.5) |
| Dyslipidaemia | 147 | 764.4 | 19.2 (16.2 to 22.6) |
| Diabetes mellitus type 2 | 99 | 510.3 | 19.4 (15.8 to 23.6) |
| Coronary artery disease | 75 | 397.5 | 18.9 (14.8 to 23.7) |
| Cerebrovascular disease | 39 | 216.9 | 18.0 (12.8 to 24.6) |
| Congestive heart failure | 28 | 144.3 | 19.4 (12.9 to 28.1) |
| Nephrolithiasis | 41 | 171.2 | 23.9 (17.2 to 32.5) |
| Renal colic | 34 | 140.3 | 24.2 (16.8 to 33.9) |
| Chronic renal failure | 167 | 815.3 | 20.5 (17.5 to 23.8) |
| Concomitant use of anti-gout drug* | |||
| Allopurinol | 425 | 1914.6 | 22.2 (20.1 to 24.4) |
| Colchicine | 128 | 606.6 | 21.1 (17.6 to 25.1) |
| NSAIDs | 552 | 2070.1 | 26.7 (24.5 to 29.0) |
| Corticosteroids | 18 | 109.4 | 16.5 (9.8 to 26.0) |
| Concomitant use of other drugs† | |||
| Diuretics | 137 | 714.6 | 19.2 (16.1 to 22.7) |
| Salicylates | 124 | 655.7 | 18.9 (15.7 to 22.5) |
| Oral anticoagulants | 26 | 176.6 | 14.7 (9.6 to 21.6) |
| Ciclosporin | 4 | 11.0 | 36.4 (9.9 to 93.2) |
| Broad-spectrum penicillins | 40 | 174.1 | 23.0 (16.4 to 31.3) |
| Imidazole derivatives | 7 | 25.8 | 27.2 (10.9 to 56.0) |
| Levodopa | 2 | 11.3 | 17.8 (2.2 to 64.2) |
| Body mass index | |||
| Missing data | 414 | 2100.3 | 19.7 (17.8 to 21.7) |
| Underweight (<18.5) | 0 | 8.2 | – |
| Normal weight (18.5–24.9) | 43 | 235.3 | 18.3 (13.2 to 24.6) |
| Overweight (25–29.9) | 71 | 450.9 | 15.7 (12.3 to 19.9) |
| Obese (>30) | 48 | 216.9 | 22.1 (16.3 to 29.3) |
| Uricaemia‡ | |||
| Missing data | 170 | 1026.3 | 16.6 (14.2 to 19.2) |
| <6 mg/dl | 56 | 329.2 | 17 (12.8 to 22.1) |
| 6–7 mg/dl | 42 | 216.0 | 19.4 (14.0 to 26.3) |
| >7–9 mg/dl | 172 | 865.6 | 19.9 (17.0 to 23.1) |
| >9 mg/dl | 136 | 574.4 | 23.7 (19.9 to 28.0) |